362 related articles for article (PubMed ID: 30799590)
1. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
[TBL] [Abstract][Full Text] [Related]
2. Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group.
Pharithi RB; Ranganathan D; O'Brien J; Egom EE; Burke C; Ryan D; McAuliffe C; Vaughan M; Coughlan T; Morrissey E; McHugh J; Moore D; Collins R
Ir J Med Sci; 2019 Feb; 188(1):101-108. PubMed ID: 29860595
[TBL] [Abstract][Full Text] [Related]
3. Appropriateness of prescribing profiles and intake adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: analysis of a retrospective longitudinal study using real-world data from Northern Portugal (AF-React Study).
Silva Pinto S; Henriques TS; Teixeira ASC; Monteiro H; Martins C
BMJ Open; 2024 Apr; 14(4):e076108. PubMed ID: 38688672
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
6. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
7. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
[TBL] [Abstract][Full Text] [Related]
8. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
[TBL] [Abstract][Full Text] [Related]
9. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2016 Nov; 22(11):1319-1329. PubMed ID: 27783556
[TBL] [Abstract][Full Text] [Related]
10. Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases.
Türk UÖ; Acar RD; Akgün T; Emren V; Kanat S; Karacağlar E; Kepez A; Kul Ş; Özel E; Şimşek E; Yakar Tülüce S; Tülüce K; Camm AJ
Turk Kardiyol Dern Ars; 2020 Apr; 48(3):289-303. PubMed ID: 32281950
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies.
Morimoto T; Crawford B; Wada K; Ueda S
J Cardiol; 2015 Dec; 66(6):466-74. PubMed ID: 26162944
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of indications for reduced-dose non-vitamin K antagonist oral anticoagulants in hospitalised patients with atrial fibrillation.
Jelonek O; Gorczyca I; Bączek M; Kośmider P; Wożakowska-Kapłon B
Kardiol Pol; 2018; 76(7):1073-1080. PubMed ID: 29441513
[TBL] [Abstract][Full Text] [Related]
13. Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation.
Park S; Je NK
J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):656-664. PubMed ID: 34558337
[TBL] [Abstract][Full Text] [Related]
14. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
15. The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article.
Liu X; Huang M; Ye C; Zeng J; Zeng C; Ma J
Medicine (Baltimore); 2020 Jul; 99(27):e21025. PubMed ID: 32629725
[TBL] [Abstract][Full Text] [Related]
16. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
García Rodríguez LA; Martín-Pérez M; Vora P; Roberts L; Balabanova Y; Brobert G; Fatoba S; Suzart-Woischnik K; Schaefer B; Ruigomez A
BMJ Open; 2019 Sep; 9(9):e031341. PubMed ID: 31542760
[TBL] [Abstract][Full Text] [Related]
17. Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.
Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli G; Reiffel J; Singer DE; Peterson ED; Piccini JP;
J Am Coll Cardiol; 2016 Dec; 68(24):2597-2604. PubMed ID: 27978942
[TBL] [Abstract][Full Text] [Related]
18. Changes in Oral Anticoagulation Therapy over One Year in 51,000 Atrial Fibrillation Patients at Risk for Stroke: A Practice-Derived Study.
Hohnloser SH; Basic E; Nabauer M
Thromb Haemost; 2019 Jun; 119(6):882-893. PubMed ID: 30900220
[TBL] [Abstract][Full Text] [Related]
19. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study.
Staerk L; Gerds TA; Lip GYH; Ozenne B; Bonde AN; Lamberts M; Fosbøl EL; Torp-Pedersen C; Gislason GH; Olesen JB
J Intern Med; 2018 Jan; 283(1):45-55. PubMed ID: 28861925
[TBL] [Abstract][Full Text] [Related]
20. Label Adherence of Direct Oral Anticoagulants Dosing and Clinical Outcomes in Patients With Atrial Fibrillation.
Yu HT; Yang PS; Jang E; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Lip GYH; Joung B
J Am Heart Assoc; 2020 Jun; 9(12):e014177. PubMed ID: 32495677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
